TIVC Overview

New Patent Applications: Tivic Health Systems has filed two patent applications, one for TLR5 agonists like Entolimod and Entolasta to enhance cancer therapy outcomes, and another for optimized specifications of a non-invasive vagus nerve stimulation device.

Potential Benefits for Cancer Patients: The TLR5 agonists may serve as adjunctive therapies to improve the effectiveness of immuno-oncology treatments for late-stage cancer patients who are often immunocompromised.

Focus on Intellectual Property and Partnerships: CEO Jennifer Ernst emphasized the importance of expanding their intellectual property rights to create new partnership opportunities and market potential for their product candidates.

Overview of Tivic's Therapeutics: Tivic Health utilizes both biopharmaceutical and bioelectronic systems to address unmet medical needs, with a focus on enhancing immune responses and developing non-invasive medical devices for various diseases.

Earnings Announcement: Tivic Health Systems, Inc. will report its third quarter results for 2025 on November 14, 2025, via a pre-recorded conference call and webcast.

Company Overview: Tivic Health focuses on immunotherapeutics, utilizing both biopharmaceutical and bioelectronic systems to address unmet medical needs, particularly through its lead drug candidate, Entolimod™.

Innovative Approaches: The company is developing a non-invasive medical device aimed at regulating neural pathways related to various diseases, with early trials indicating promising results.

Forward-Looking Statements: The press release includes forward-looking statements that carry risks and uncertainties, advising caution in reliance on these projections.